Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
113.58
+0.89 (0.79%)
Oct 6, 2025, 4:00 PM EDT - Market closed
Gilead Sciences Revenue
Gilead Sciences had revenue of $7.08B in the quarter ending June 30, 2025, with 1.84% growth. This brings the company's revenue in the last twelve months to $28.86B, up 3.81% year-over-year. In the year 2024, Gilead Sciences had annual revenue of $28.75B with 6.04% growth.
Revenue (ttm)
$28.86B
Revenue Growth
+3.81%
P/S Ratio
4.91
Revenue / Employee
$1,639,943
Employees
17,600
Market Cap
140.93B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
GILD News
- 16 hours ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 6 days ago - Dividend Shields: Top 5 Income Stocks - Seeking Alpha
- 8 days ago - Hanmi's Oral Delivery Platform Compound Licensed to Gilead - PRNewsWire
- 11 days ago - Gilead Foundation Grants $6.5 Million in Commitment to STEM Education - Business Wire
- 13 days ago - Gilead Sciences: Yeztugo And Trodelvy Make This A Buy Once More - Seeking Alpha
- 19 days ago - Fangzhou Wins Gilead ‘Award of Excellence' for AI-Driven Chronic Disease Management - GlobeNewsWire
- 26 days ago - Gilead Sciences, Inc. (GILD) Presents At Baird Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 27 days ago - Gilead Sciences, Inc. (GILD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha